Company will conduct Phase 3 trial of AMO-02 (tideglusib) in adults to support a future submission for marketing authorization in Type 1 myotonic dystrophy in both adult and pediatric indications.
Company now enrolling patients at leading research centers in Canada as well as in the United States LONDON, May 17, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback